miltefosine has been researched along with AIDS-Related Opportunistic Infections in 6 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 6.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "There is still no effective treatment for cryptosporidiosis even though the disease has a significant impact on HIV-infected adults and children." | 2.76 | In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality. ( Katubulushi, M; Kelly, P; Obwaller, A; Sianongo, S; Sinkala, E, 2011) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "We carried out a retrospective and descriptive study of 4 HIV infected patients with relapsing visceral leishmaniasis (VL) seen at 2 tertiary-care hospitals in Spain during the last 6 y, in whom miltefosine was used as a compassionate use treatment at a dosage of 50 mg b." | 1.35 | Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. ( Casquero, A; Fernández-Guerrero, ML; Górgolas, M; Refoyo, E; Troya, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guffanti, M | 1 |
| Gaiera, G | 1 |
| Bossolasco, S | 1 |
| Ceserani, N | 1 |
| Ratti, D | 1 |
| Cinque, P | 1 |
| Salmaso, F | 1 |
| Gianotti, N | 1 |
| Lazzarin, A | 1 |
| Collini, P | 1 |
| Premchand, N | 1 |
| Lockwood, D | 1 |
| Greig, J | 1 |
| Barragán, P | 1 |
| López-Velez, R | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Sinkala, E | 1 |
| Katubulushi, M | 1 |
| Sianongo, S | 1 |
| Obwaller, A | 1 |
| Kelly, P | 1 |
| Rosenthal, E | 1 |
| Marty, P | 1 |
| Troya, J | 1 |
| Casquero, A | 1 |
| Refoyo, E | 1 |
| Fernández-Guerrero, ML | 1 |
| Górgolas, M | 1 |
2 reviews available for miltefosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug | 2009 |
[Visceral leishmaniases].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antimony; Antiprotozoal Agent | 2004 |
1 trial available for miltefosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptosporidiosis; Diarrhea; Early Termination of Clin | 2011 |
3 other studies available for miltefosine and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antiparasitic Ag | 2008 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiprotozoal Agents; Bone Marrow; Female; HI | 2008 |